Navigation Links
Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
Date:8/19/2007

Pharmatek Now Offers Contract Cytotoxic & High-Potent Analytical,

Formulation and Manufacturing Services

SAN DIEGO, Aug. 16 /PRNewswire/ -- Pharmatek Laboratories, Inc. today announced the addition of cytotoxic and high-potent drug development capabilities to its pharmaceutical chemistry development services. Cytotoxic and high-potent services include analytical method development, preformulation testing, formulation development, manufacturing for early phase clinical trials, release testing, and stability testing and storage.

"This expansion was driven by an increase in demand for cytotoxic and high-potent drug development and manufacturing outsourcing among our clients," said Dr. Jeffrey Bibbs, CEO of Pharmatek. "This added capability enables us to provide a broader level of services to our clients with cytotoxic and high-potent candidates."

Pharmatek's cytotoxic and high-potent development services will be carried out in a separate dedicated facility. Manufacturing capability includes two validated and licensed class 100,000 high-containment suites designed with barrier technology for cGMP manufacturing of final form drug products. Dedicated HVAC and HEPA filtration systems ensure product containment within the suites. Personnel are protected through strict gowning and control procedures to ensure employee safety while working in the suites.

"Pharmatek has been a valued resource for the development and manufacturing of non-potent drugs for more than eight years," said Timothy Scott, president of Pharmatek. "This investment positions Pharmatek to become a leading cytotoxic and high-potent drug development service provider."

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discov
'/>"/>

SOURCE Pharmatek Laboratories, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43)
2. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
3. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
4. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
5. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
6. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
7. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
8. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
9. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
10. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
11. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in ... big ideas for 2014 in production and sales of ... produce high-quality, low-cost, DRM-free ebooks and to use the ... The first major development will be bookstore sales in ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 12 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), ... the treatment of cancer and,hepatitis C virus infection ... its clinical trial designed to evaluate the safety ... patients with advanced,breast cancer. The primary objective of ...
... Calif., Feb. 12 Ardea Biosciences,Inc. (Nasdaq: RDEA ) ... Ardea Biosciences, will present at the Roth Capital Partners,20th Annual ... 19, 2008 Time: 4:00 p.m. Pacific Time ... Webcast: http://www.wsw.com/webcast/roth16/rdea/ or ...
... Also Announced, SILVER SPRING, Md., Feb. 12 ... today that it will,release its 2007 fourth quarter ... on Tuesday, February 19, 2008., United Therapeutics ... 2008, at 9:00 a.m. Eastern Time. The teleconference ...
Cached Biology Technology:Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 4Ardea Biosciences to Present at Roth Capital Partners' 20th Annual OC Growth Stock Conference 2
(Date:4/22/2014)... This news release is available in French . ... less than a month, sequencing of the complete genome ... in Guinea forms a clade (variant) that is distinct ... Congo and in Gabon. Epidemiological investigations also linked the ... the December 2013 outbreak. , Ebola virus is a ...
(Date:4/22/2014)... projects in two Minnesota cities demonstrate how communities ... continue a ten year program in New England ... tailored to local conditions. , "Our goal is ... themselves," said program co-leader Latham Stack, of Syntectic ... already worsened. We help communities move beyond feeling ...
(Date:4/22/2014)... Most people think the development of the heart only ... birth are full of cellular changes that play a role ... models, researchers at Baylor College of Medicine have now been ... genes code proteins, determining their role) that takes place during ... The findings, which appear in Nature Communications , also ...
Breaking Biology News(10 mins):Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2Minnesota projects offer hope and practical help to communities facing more extreme storms 2Protein expression gets the heart pumping 2
... pink to traditional French and Lady Gaga,s sophisticated designs, manicured ... are not just pretty when nails appeared on all ... ago, they led to the development of critical functions, including ... to grasp, whether it,s a nail polish brush or remover ...
... of produce may not be enough to remove harmful food ... Salmonella and E. coli can live inside plant ... in tissues of mung bean sprouts and Salmonella in peanut ... prior to planting. Amanda Deering, a postdoctoral researcher in food ...
... might be a time when instead of just drinking that ... as a way of preventing harmful sun damage or skin ... guards against certain skin cancers at the molecular level by ... Scientists believe that based on what they have learned studying ...
Cached Biology News:Researchers discover oldest evidence of nails in modern primates 2Researchers discover oldest evidence of nails in modern primates 3E. coli, salmonella may lurk in unwashable places in produce 2More evidence that caffeine lowers risk of skin cancer 2